| Name | statins |
|---|---|
| Synonyms | STN; statin; statins |
| Name | ACC |
|---|---|
| CAS | 1-aminocyclopropanecarboxylic acid |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 18439049 | Lee HY, Cooke CE, Robertson TA: Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm. 2008 Apr;14(3):271-80. The American College of Cardiology/American Heart Association (ACC/AHA) guidelines on the management of patients with unstable angina and non-ST-segment elevation myocardial infarction (2002-2004) recommend (1) angiotensinconverting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) for ACE inhibitor intolerance, (2) beta-blockers, and (3) statins for long-term treatment of patients after an acute coronary event. |
5(0,0,0,5) | Details |
| 18345999 | Cho L, Hoogwerf B, Huang J, Brennan DM, Hazen SL: Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study. J Womens Health. 2008 May;17(4):515-21. The primary objective was to evaluate use of effective secondary preventive therapies, by gender, as outlined in the ACC/AHA guidelines, such as antiplatelet therapy, beta-blockers, statins, and angiotensin-converting enzyme (ACE) inhibitors. |
2(0,0,0,2) | Details |
| 17654318 | Gowdak LH, Arantes RL, de Paula FJ, Krieger EM, De Lima JJ: Underuse of American College of Cardiology/American Heart Association Guidelines in hemodialysis patients. Ren Fail. 2007;29(5):559-65. The use of angiotensin-converting enzyme inhibitors (ACE-I), beta-blockers, and statins was assessed in 271 (72% males, 66% Caucasians) high-risk ESRD patients on hemodialysis. |
2(0,0,0,2) | Details |
| 19498441 | Izumi Y, Shiota M, Kusakabe H, Hikita Y, Nakao T, Nakamura Y, Muro T, Miura K, Yoshiyama M, Iwao H: accelerates ischemia-induced angiogenesis through AMP-activated protein kinase. Hypertens Res. 2009 Aug;32(8):675-9. Epub 2009 Jun 5. Statins exert pleiotropic effects on the cardiovascular system, in part through an increase in (NO) bioavailability. |
2(0,0,0,2) | Details |
| 18751508 | Timoteo AT, Fiarresga A, Feliciano J, Ferreira ML, Oliveira JA, Serra J, Ferreira R: Adherence to guidelines in the treatment of acute coronary syndromes: progress over time. Rev Port Cardiol. 2008 Jun;27(6):803-12. Treatment with (6% vs. 87%), beta-blockers (54% vs. 79%), angiotensin-converting enzyme inhibitors (72% vs. 84%) and statins (78% vs. 91%) increased (all with p < 0.001). |
2(0,0,0,2) | Details |
| 18599796 | Li X, Han Y, Pang W, Li C, Xie X, Shyy JY, Zhu Y: AMP-activated protein kinase promotes the differentiation of endothelial progenitor cells. Arterioscler Thromb Vasc Biol. 2008 Oct;28(10):1789-95. Epub 2008 Jul 3. CONCLUSIONS: The activation of eNOS by AMPK during EPC differentiation provides a novel mechanism for the pleiotropic effects of statins in benefiting the cardiovascular system. |
1(0,0,0,1) | Details |
| 19561793 | David RB: American college of cardiology 57th scientific sessions, 2008. P T. 2008 May;33(5):296-8. The ENHANCE findings intensified interest in both non-lipid-lowering benefits of statins and non-statins for lipid lowering. |
1(0,0,0,1) | Details |
| 19069375 | Ortega-Gil J, Perez-Cardona JM: Unstable angina and non ST elevation acute coronary syndromes. P R Health Sci J. 2008 Dec;27(4):395-401. Evidence base scientific data insists upon using aggressive medical therapy (statins, anti-platelets, beta blockers [BBs], angiotensin converting enzyme inhibitors [ACE-Is], and control of coronary risk factors) as well as mechanical reperfusion, whether by percutaneous coronary intervention (PCI) or by coronary artery bypass graft (CABG). |
1(0,0,0,1) | Details |
| 18180524 | Cohen M, Diez JE, Levine GN, Ferguson JJ 3rd, Morrow DA, Rao SV, Zidar JP: Pharmacoinvasive management of acute coronary syndrome: incorporating the 2007 ACC/AHA guidelines: the CATH (cardiac catheterization and antithrombotic therapy in the hospital) Clinical Consensus Panel Report--III. J Invasive Cardiol. 2007 Dec;19(12):525-38; quiz 539-40. The addition of statins, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers is also stressed as part of a comprehensive secondary cardioprotective strategy for patients with coronary heart disease. |
1(0,0,0,1) | Details |